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Avastin in myopic choroidal
neovascularisation: is age the
limit?
David Wong,1,2 Kenneth K W Li1
There are a growing number of publica-
tions supporting the use of Avastin
(bevacizumab) for choroidal neovascular-
isation (CNV) secondary to pathological
myopia (table 1).1–8 In this issue, Arias et al
(see page 1035) reported a prospective
study of 17 patients;9 at the 6-month
follow-up, the mean Early Treatment
Diabetic Retinopathy Study visual acuity
improved by 8.4 letters (p = 0.04), and the
mean optical coherence tomography
(OCT) foveal thickness decreased by
79.6 mm (p = 0.002). Is it time to change
our clinical practice? Is it time to abandon
photodynamic therapy (PDT) as the first
line treatment? The purist would say that
the only evidence base from randomised
controlled trials is still that provided by
the Verteporfin in Photodynamic Therapy
(VIP) Study.10 11 In this study, PDT was
shown to be effective in preventing visual
loss fewer than eight letters in pathologi-
cal myopia in the first year when com-
pared with sham treatment.10 However,
the effect of PDT was not sustained by
the end of the second year.11 Smaller case
series have shown similar results.11 Other
investigators have attempted to improve
the efficacy of PDT by enhancing the
fluence13 or combining PDT with intravi-
treal triamcinolone acetonide injec-
tion.14 15 These studies failed to persuade,
either limited by the small number of
patients or because the results were
inconsistent.
But do all CNV secondary to patholo-
gical myopia have a similar prognosis and
response to treatment? The report on the
natural history of untreated CNV second-
ary to pathological myopia by Kojima et al
is now recognised as a landmark paper.16
Using regression analysis, they investi-
gated the prognostic factor in 54
untreated eyes in 54 patients in Japan
(prior to PDT being available) and found
that the best corrected visual acuity
(BCVA) at 5 years after onset was sig-
nificantly associated with patient age,
CNV size and initial BCVA (p,0.05,
Spearman correlation). In a retrospective
study, Yoshida et al also examined the
effect of age on the natural history of
CNV secondary to pathological myopia.17
They found that patients under the age of
40 had significant better visual outcome
than patients over the age of 40. Their
results need to be interpreted carefully, as
they included both juxtafoveal and sub-
foveal cases. The authors nonetheless
raised the important point that the visual
prognosis of CNV secondary to patholo-
gical myopia was not always consistent.
The angiographic features of the CNV in
patients over the age of 40 had a more
profuse angiographic leakage. Other inves-
tigators have studied the effect of age on
the visual outcome of treatment of CNV
secondary to pathological myopia with
PDT. Axer-Siegel et al, in a retrospective
study, found that 50% of the older age
group and 20% of the younger age group
had visual loss of 15 letters or more, and
the difference was significant; however,
8% of the younger patients in the series of
Axer-Siegel et al continued to lose 15 or
more letters despite treatment with
PDT.18
In the VIP study, less than 25% improve
one or more lines at 3 months.9 A treat-
ment primarily aimed at preventing visual
loss is likely to disappoint patients seeking
to have their vision restored. In the wake
of several case series reporting visual
improvement with the use of Avastin,
more and more physicians are persuaded
to change from PDT to the off-label use of
anti-vascular endothelial growth factor
(VEGF) agents for CNV in pathological
myopia.1–8 Until now, these interventional
studies have relatively short follow-up of
6 months. We do not yet know whether
multiple injections will eventually alter
the natural history favourably.
In the absence of an evidence base
derived from randomised controlled trial
supporting the use of Avastin for CNV
secondary to pathological myopia, in
patients with good vision at least, some
may feel obliged to use PDT as the first-
line treatment. But in older patients, with
larger subfoveal CNV and more signifi-
cant visual loss, our threshold for switch-
ing to or even adding Avastin may be
lowered. It is noteworthy that Arias et al
found that patients aged (50 years
improved by a mean of 8.7 letters
(p = 0.13), and patients older than
50 years improved by a mean of 8.3 letters
(p = 0.1). Avastin seemed to be effective
in older patients, whereas PDT might be
limited by age.
The use of anti-VEGF off-label for age-
related macular degeneration is still
fraught with ethical difficulties and fund-
ing problems within the National Health
Service (NHS) in the UK.19 If we were to
use an anti-VEGF, we of course have a
choice of bevacizumab, ranibizumab and
pegatanib, all of which are off-label
treatments to CNV secondary to patho-
logical myopia, and thus far, there are no
publications on the efficacy of latter two
agents. Rosenfeld pointed out that
Genentech or Roche should not be
expected to pay for an intravitreal
Avastin clinical trial unless they plan to
seek a labelled indication for Avastin in
ophthalmology, which seems unlikely.20
Rather, the cost of such a trial is a societal
responsibility of those agencies and gov-
ernments that stand to benefit from
preventing vision loss from neovascular-
isation in pathological myopia. In the UK,
the Inhibit VEGF in Age-related choroidal
Neovascularisation (IVAN) trial is set up
to study CNV secondary to age-related
macular degeneration and funded by the
Health Technology Assessment Clinical
Trials Programme of the UK National
Institute for Health Research.21 The IVAN
trial compares: (a) an inexpensive drug,
bevacizumab used ‘‘off-label’’ with an
expensive licensed drug, ranibizumab,
and (b) continuous monthly treatment
with reduced frequency of treatment. The
trial has high research costs, but this
investment by the NHS represents good
value when set against potential savings
to the NHS should the less expensive
drug, or reduced treatment frequency, be
shown to be as effective as the more
expensive alternatives. The success of this
trial is reliant on a network of hospitals
and consultants working together. This
network covers all of the UK and is
perfectly positioned to mount an intravi-
treal Avastin trial on CNV in pathological
myopia. The VIP trial was probably
underpowered, recruiting 120 patients,
randomising 81 patients to PDT and 36
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to sham treatment. It will take the
concerted effort of all the consultants in
UK to recruit sufficient patients to get a
meaningful result. In the mean time, we
can only treat patients individually on
their merit, as not all CNV secondary to
pathological myopia have the same prog-
nosis or response.
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Table 1 Summary of published studies on the use of Avastin (bevacizumab) in the treatment of choroidal neovascularisation secondary to
pathological myopia
Year Author Study No. of cases Dosage (mg)/no. of injections Follow-up period (months)
2006 Laud et al1 Case report 4 1.25/2–3 7.3
2006 Tewari et al2 Case report 1 1.25/2 6
2007 Yamamoto et al3 Retrospective 11 1.25/1–2 5.5
2007 Sakaguchi et al4 Prospective 8 1/1–2 4.4
2007 Hernandez-Rojas et al5 Prospective 14 2.5/>1 3
2007 Mandal et al6 Prospective 12 1.25/1+ as necessary 6
2007 Chan et al7 Prospective 22 1.25/3 6
2007 Ruiz-Moreno et al8 Prospective 26 1.25/3 6
2008 Arias et al Prospective 17 1.25/1.1 6
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